The EFCAB14 Knockout HeLa Polyclonal Cells product offers a polyclonal HeLa cell population with CRISPR/Cas9-mediated disruption of the EFCAB14 gene, enabling loss-of-function analysis of this EF-hand calcium-binding protein. As a polyclonal knockout pool, it provides a diverse genetic background suitable for robust functional studies without the limitations of clonal selection. This model is amenable to various downstream applications, including gene expression profiling and phenotypic assays.
The host HeLa cell line, derived from HPV-18-positive cervical adenocarcinoma, is an immortalized epithelial line extensively utilized in biomedical research. Its well-characterized biology and robust growth make it ideal for CRISPR-based gene knockout, especially for exploring calcium signaling in an epithelial cancer context.
EFCAB14 encodes a calcium-binding protein with predicted EF-hand domains that function as calcium sensors, interacting with calcium ions and calmodulin. It operates upstream of effectors such as CaMKII and axonemal dyneins, linking it to calcium signal transduction and motile cilia function. The gene is regulated by FOXJ1 and may be influenced by sex hormones, situating it within ciliogenic and reproductive signaling networks. Related pathways include calcium, cAMP, and sperm motility signaling.
In HeLa cells, EFCAB14 knockout provides a model to investigate calcium-dependent signaling that may impact cancer cell phenotypes. Under serum starvation, HeLa cells can form primary cilia, allowing studies of ciliary dynamics. Disruption may alter calcium flux, cell motility, and phospho-signaling, offering insights into calcium-binding protein roles in epithelial cells. Additionally, the model can inform mechanisms relevant to male infertility given EFCAB14’s role in sperm motility.
Applications include validation of knockout by RT-qPCR and Western blot, calcium imaging and flux assays to assess calcium homeostasis, co-immunoprecipitation for calmodulin interactions, and cell motility assays. The model is suitable for drug screening targeting calcium channels or calcium-dependent pathways in cancer. For pricing, technical specifications, or support, please contact Ascent Research.
